These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11512521)

  • 21. Apoptotic pathways and therapy resistance in human malignancies.
    Viktorsson K; Lewensohn R; Zhivotovsky B
    Adv Cancer Res; 2005; 94():143-96. PubMed ID: 16096001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clusterin inhibits apoptosis by interacting with activated Bax.
    Zhang H; Kim JK; Edwards CA; Xu Z; Taichman R; Wang CY
    Nat Cell Biol; 2005 Sep; 7(9):909-15. PubMed ID: 16113678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
    Herst PM; Hesketh EL; Ritchie DS; Berridge MV
    Leuk Res; 2008 Feb; 32(2):327-33. PubMed ID: 17580091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance in hematologic malignancies.
    Dalton W
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
    [No Abstract]   [Full Text] [Related]  

  • 25. Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models.
    Beasley GM; Kahn L; Tyler DS
    Surg Oncol Clin N Am; 2008 Oct; 17(4):731-58, vii-viii. PubMed ID: 18722915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracellular matrix regulation of drug resistance in small-cell lung cancer.
    Rintoul RC; Sethi T
    Clin Sci (Lond); 2002 Apr; 102(4):417-24. PubMed ID: 11914104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide.
    Brumatti G; Yon M; Castro FA; Bueno-da-Silva AE; Jacysyn JF; Brunner T; Amarante-Mendes GP
    Exp Cell Res; 2008 Feb; 314(3):554-63. PubMed ID: 18078929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of tetrandrine and droloxifene on the reversion of drug resistance of K562/A02 cell line and induction of apoptosis].
    Chen B; Dong Y; Zhang P; Cheng J; Zhou Y; Sheng M; Wang T; Gao F
    Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):526-8. PubMed ID: 12667316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the effectiveness of mono- and polychemotherapy for murine lymphosarcoma, resistant to apoptosis induction].
    Kaledin VI; Popova NA; Andreeva EM
    Vopr Onkol; 2006; 52(1):70-3. PubMed ID: 16715708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line.
    Wu GS; Ding Z
    Oncogene; 2002 Jan; 21(1):1-8. PubMed ID: 11791171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antimitochondrial agents: a new class of anticancer agents].
    André N; Rome A; Carré M;
    Arch Pediatr; 2006 Jan; 13(1):69-75. PubMed ID: 16298120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction to resistance to anticancer agents.
    Kruh GD
    Oncogene; 2003 Oct; 22(47):7262-4. PubMed ID: 14576836
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition.
    Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C
    Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
    Elliott T; Sethi T
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
    Styczynski J; Koltan A; Wysocki M
    Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
    Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
    Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells.
    Wang G; Shang HL; Xie Y; Xiao P; Li XJ; Lin TC; Li GY
    Chin Med J (Engl); 2005 Feb; 118(4):333-6. PubMed ID: 15740674
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
    Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
    Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling therapy resistance in genetically engineered mouse cancer models.
    Rottenberg S; Jonkers J
    Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug resistance and cell survival mechanisms for anticancer drugs].
    Sakai T
    Nihon Yakurigaku Zasshi; 2006 May; 127(5):342-7. PubMed ID: 16819238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.